Parenteral broadcasts of carvedilol dispersions

JP2026090530APending Publication Date: 2026-06-02ASCENDIA PHARMACEUTICALS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ASCENDIA PHARMACEUTICALS LLC
Filing Date
2026-02-27
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Current treatments for hypertensive emergencies, such as those using carvedilol, face challenges with rapid onset and hypotension risks, and lack of parenteral formulations, leading to suboptimal management of acute cardiovascular events.

Method used

Development of parenteral drug delivery systems for carvedilol, including liposomes, biodegradable micro/nanoparticles, and micelles, providing extended in vitro and in vivo release and longer residence time.

Benefits of technology

The formulations achieve sustained release and improved bioavailability, reducing side effects and enhancing therapeutic efficacy in managing hypertension and heart failure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026090530000014
    Figure 2026090530000014
  • Figure 2026090530000015
    Figure 2026090530000015
  • Figure 2026090530000016
    Figure 2026090530000016
Patent Text Reader

Abstract

This provides a parenteral dosage form of carvedilol. [Solution] A parenteral sustained-release system of carvedilol via IV injection, injection, or subcutaneous route is disclosed. Preparations of carvedilol dispersion systems such as liposomes, biodegradable microparticles or nanoparticles, and polymer microparticles or nanoparticles are shown in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rates than the free solution after intravenous administration. In vitro release of these liposomes in buffer solution showed long-acting drug release over 48 hours, and correspondingly, in vivo animal data showed that parenteral administration of carvedilol encapsulated in liposome material has a sustained-release PK profile.
Need to check novelty before this filing date? Find Prior Art